- Home
- CRDF vs ONDS Comparison
CRDF vs ONDS Comparison
Compare CRDF & ONDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- ONDS
- Stock Information
- Founded
- CRDF 1999
- ONDS 2014
- Country
- CRDF United States
- ONDS United States
- Employees
- CRDF N/A
- ONDS N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- ONDS Telecommunications Equipment
- Sector
- CRDF Health Care
- ONDS Telecommunications
- Exchange
- CRDF Nasdaq
- ONDS Nasdaq
- Market Cap
- CRDF 288.7M
- ONDS 108.4M
- IPO Year
- CRDF N/A
- ONDS N/A
- Fundamental
- Price
- CRDF $4.19
- ONDS $0.70
- Analyst Decision
- CRDF Strong Buy
- ONDS Buy
- Analyst Count
- CRDF 4
- ONDS 1
- Target Price
- CRDF $12.00
- ONDS $4.00
- AVG Volume (30 Days)
- CRDF 1.1M
- ONDS 8.6M
- Earning Date
- CRDF 05-01-2025
- ONDS 03-12-2025
- Dividend Yield
- CRDF N/A
- ONDS N/A
- EPS Growth
- CRDF N/A
- ONDS N/A
- EPS
- CRDF N/A
- ONDS N/A
- Revenue
- CRDF $683,000.00
- ONDS $7,192,694.00
- Revenue This Year
- CRDF N/A
- ONDS N/A
- Revenue Next Year
- CRDF N/A
- ONDS $279.57
- P/E Ratio
- CRDF N/A
- ONDS N/A
- Revenue Growth
- CRDF 39.96
- ONDS N/A
- 52 Week Low
- CRDF $2.01
- ONDS $0.54
- 52 Week High
- CRDF $6.42
- ONDS $3.40
- Technical
- Relative Strength Index (RSI)
- CRDF 48.00
- ONDS 23.51
- Support Level
- CRDF $3.52
- ONDS $0.79
- Resistance Level
- CRDF $4.31
- ONDS $1.18
- Average True Range (ATR)
- CRDF 0.36
- ONDS 0.16
- MACD
- CRDF -0.07
- ONDS -0.03
- Stochastic Oscillator
- CRDF 28.57
- ONDS 0.02
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
About ONDS Ondas Holdings Inc.
Ondas Holdings Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system.